A Case Report of MPO-ANCAAssociated Vasculitis Following Heterologous mRNA1273 COVID-19Booster Vaccination
10.3346/jkms.2022.37.e204
- Author:
Beop Chang KIM
1
;
Han Seong KIM
;
Kum Hyun HAN
;
Sang Youb HAN
;
Hyung Ah JO
Author Information
1. Division of Nephrology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea
- Publication Type:Case Report
- From:Journal of Korean Medical Science
2022;37(26):e204-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Despite that clinical trials have been examining the safety profile of coronavirus disease 2019 (COVID-19) vaccines, there are concerns about long-term side effects as the number of vaccinations increases. Herein, we report a case of new-onset renal-limited antimyeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis after booster vaccination with the mRNA 1273 (Moderna) vaccine. A 72-year-old woman with no specific past history, and who had a normal renal function, developed ANCAassociated vasculitis following heterologous booster with mRNA1273 (Moderna) vaccine.After a kidney biopsy, she was diagnosed with ANCA-associated pauci-immune crescentic glomerulonephritis. Her renal function and constitutional symptoms have been improved with treatment with plasmapheresis, intravenous cyclophosphamide and steroid pulse therapy (intravenous 500 mg of methylprednisolone sodium succinate for 3 days) followed by a reduced steroid regimen.
